The analyzed groups (geriatric control and patients with frailty syndrome and sarcopenia) all had significantly different mRNA levels of PTGS2 compared with healthy subjects at age 25–30 and above 50 years old (Figure 3A). The gene discussed is PTGS2; the disease is sarcopenia.